B. longum: stool frequency and constipation
Results for BB536, CLA8013 and HT-ES1 for stool and digestive complaints.
Key points
- In adults prone to constipation, inactivated CLA8013 increased stool frequency over two weeks by about 0.65 times per week more than placebo. This is less than one additional time per week on average. [1] See the evidence 1
- In healthy adults with different baseline stool frequencies, the average in week two on live BB536 was 5.38 versus 4.63 times per week with placebo. The difference was 0.75 times per week for the microcapsules studied. [2] See the evidence 1
- In people aged 65 and older with chronic constipation, BB536 over four weeks did not change the overall constipation score significantly more than placebo. No advantage was found for this measure. [3] See the evidence 1
Practical guide
Check the findings and their applicability to your situation.
The studies differed in strain, form and participant group.
Key points
Why these conclusions
Stool frequency and complaints
Adults prone to constipation took 25 billion equivalents of inactivated CLA8013 cells daily or placebo for two weeks. Frequency increased by 1.16 versus 0.51 times per week; certainty is low — 2 out of 4. [1]
Healthy adults with baseline stool frequency of 3–5 or at least 7 times per week took about 5 billion CFU of live BB536 in microcapsules. In week two, frequency was 5.38 versus 4.63 times per week with placebo; certainty is 3 out of 4. [2]
In older people with chronic constipation, at least 50 billion CFU of BB536 daily for four weeks produced no significant advantage for the overall constipation score. In healthy adults with mild complaints, inactivated HT-ES1 over eight weeks also did not differ from placebo on the overall digestive complaints score; certainty for each result is low — 2 out of 4. [4] [3]
Stool frequency increased by 1.16 versus 0.51 times per week with placebo. The difference in changes was 0.65 times per week; p = 0.048.
| Parameter | Data |
|---|---|
| Result | Stool frequency increased by 1.16 versus 0.51 times per week with placebo. The difference in changes was 0.65 times per week; p = 0.048. |
| Participants | 120 adults aged 20–65 prone to constipation; 104 entered the final analysis |
| Form | Capsules containing heat-inactivated CLA8013 |
| Dose | 25 billion cell equivalents daily: one capsule after dinner |
| Dose basis | 25 billion cell equivalents daily: one capsule after dinner |
| Comparison | Capsule with the same excipients, without CLA8013 |
| Duration | 2 weeks |
| Certainty | 2/4: One two-week trial: the final analysis included 104 of 120 participants. People with a pronounced response to placebo were excluded before group allocation; this limits application of the result to all consumers. |
| Body of evidence | publication |
| Sources | [1] |
In week two, an average of 5.38 versus 4.63 times per week with placebo: a difference of 0.75 times per week; p = 0.0334.
| Parameter | Data |
|---|---|
| Result | In week two, an average of 5.38 versus 4.63 times per week with placebo: a difference of 0.75 times per week; p = 0.0334. |
| Participants | 24 healthy adults aged 40–60 with stool frequency of 3–5 or at least 7 times per week |
| Form | Live BB536 in microcapsules with an acid-resistant coating |
| Dose | About 5 billion CFU daily: 0.53 g of microcapsules with water |
| Dose basis | About 5 billion CFU daily: 0.53 g of microcapsules with water |
| Comparison | The same microcapsules with potato starch, without BB536 |
| Duration | Two periods of 2 weeks with a 4-week break |
| Certainty | 3/4: The same 24 people received BB536 and placebo in different periods, separated by a four-week break. The result applies to the specific microcapsules and two weeks of intake. Not all participants had constipation. |
| Body of evidence | publication |
| Sources | [2] |
After 8 weeks, the total GSRS-IBS digestive complaints score was 26.48 with HT-ES1 and 26.31 with placebo. There was no statistically significant difference between groups.
| Parameter | Data |
|---|---|
| Result | After 8 weeks, the total GSRS-IBS digestive complaints score was 26.48 with HT-ES1 and 26.31 with placebo. There was no statistically significant difference between groups. |
| Participants | 60 healthy adults aged 18–65 with mild digestive complaints; 53 completed intake per protocol |
| Form | Capsules containing heat-inactivated HT-ES1, strain CECT 7347 |
| Dose | 2.5 billion cells daily: 50 mg of material in two capsules with breakfast |
| Dose basis | 2.5 billion cells daily: 50 mg of material in two capsules with breakfast |
| Comparison | Capsules with maltodextrin, without HT-ES1 |
| Duration | 8 weeks |
| Certainty | 2/4: The final analysis included 53 people; the overall sum of different intestinal complaints was assessed. This result does not provide a separate effect size specifically for bloating. |
| Body of evidence | publication |
| Sources | [4] |
Over 4 weeks, the change in the total CSS constipation score did not differ statistically from placebo; p = 0.074.
| Parameter | Data |
|---|---|
| Result | Over 4 weeks, the change in the total CSS constipation score did not differ statistically from placebo; p = 0.074. |
| Participants | 80 people aged 65 and older with chronic constipation, including IBS with constipation; 79 entered the analysis, mean age about 78 years |
| Form | Powder containing dried live BB536 in a sachet |
| Dose | At least 50 billion CFU daily: one 2 g sachet |
| Dose basis | At least 50 billion CFU daily: one 2 g sachet |
| Comparison | Placebo powder without BB536 |
| Duration | 4 weeks |
| Certainty | 2/4: The trial included 80 older people, 79 entered the analysis. It assessed the overall constipation score. The separate stool frequency subscale changed differently, but its points cannot be converted into a number of additional trips to the toilet. |
| Body of evidence | publication |
| Sources | [3] |
Information from the source
In healthy people, live probiotics can cause gas and other intestinal complaints. Inactivated cells also do not rule out adverse reactions: the HT-ES1 trial described stomach pain, gas and a possible association with nausea, bloating and reflux. In severe illness or markedly weakened immunity, live probiotics may increase the risk of infection. In these situations, discuss product choice and monitoring with a doctor. The risk is particularly important for preterm infants: the FDA described a case of B. longum sepsis and the death of an infant after a hospital product containing live bacteria. This case does not establish the frequency of complications in healthy adults. Check not only the bacteria but also the other ingredients. For example, the CLA8013 capsule shell in the trial described contained porcine gelatin and soy lecithin; another product may have a different composition. [4] [1] [5] [6] [7]
Information from the source
Live bacteria. BB536, NCC3001, 1714, 35624, ES1, BL21 and APC1472 are different strains. Look on the package for the full code, CFU count through the end of shelf life and storage conditions. More CFU alone does not mean more benefit. Inactivated cells. CLA8013 and HT-ES1 were heat-treated in these trials. Their doses are expressed as numbers of cells or cell equivalents, not numbers of live bacteria. Even for HT-ES1, doses differed: 2.5 billion cells in digestive studies and 2 billion for allergic rhinitis. Strain 35624. In an early publication it was called B. infantis 35624. In the trial of pain in IBS, capsules containing 100 million CFU daily showed an advantage; this is not a general result for all doses or all B. longum products. [7] [1] [4] [8]
Sources
- Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study. https://pubmed.ncbi.nlm.nih.gov/37404567/
- Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT. https://pubmed.ncbi.nlm.nih.gov/36382178/
- Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/36216361/
- Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study. https://pubmed.ncbi.nlm.nih.gov/39599737/
- Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA). https://www.fda.gov/safety/medical-product-safety-information/risk-invasive-disease-preterm-infants-given-probiotics-formulated-contain-live-bacteria-or-yeast
- Probiotics: Usefulness and Safety (NCCIH). https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety
- Probiotics — Fact Sheet for Consumers (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-Consumer/
- Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. https://pubmed.ncbi.nlm.nih.gov/16863564/
Methodology: Subpages evidence-led supplement pipeline v1